PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
75.52
+1.03 (1.38%)
At close: Jul 30, 2026, 4:00 PM EDT
77.97
+2.45 (3.24%)
After-hours: Jul 30, 2026, 7:41 PM EDT
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $360.52M in the quarter ending June 30, 2026, with 101.55% growth. This brings the company's revenue in the last twelve months to $1.01B, down -42.84% year-over-year. In the year 2025, PTC Therapeutics had annual revenue of $1.73B with 114.51% growth.
Revenue (ttm)
$1.01B
Revenue Growth
-42.84%
P/S Ratio
6.21
Revenue / Employee
$1,017,915
Employees
991
Market Cap
6.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73B | 923.88M | 114.51% |
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
| Dec 31, 2018 | 264.73M | 70.34M | 36.19% |
| Dec 31, 2017 | 194.39M | 111.69M | 135.04% |
| Dec 31, 2016 | 82.71M | 45.94M | 124.95% |
| Dec 31, 2015 | 36.77M | 11.52M | 45.64% |
| Dec 31, 2014 | 25.25M | -9.45M | -27.24% |
| Dec 31, 2013 | 34.70M | 750.00K | 2.21% |
| Dec 31, 2012 | 33.95M | -71.47M | -67.80% |
| Dec 31, 2011 | 105.41M | 100.45M | 2,022.34% |
| Dec 31, 2005 | 4.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mirum Pharmaceuticals | 569.61M |
| Ligand Pharmaceuticals | 274.48M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 5.07M |
| Dianthus Therapeutics | 1.34M |
PTCT News
- 7 hours ago - PTC Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 7 hours ago - PTC Therapeutics Earnings release: Q2 2026 - Filings
- 7 hours ago - PTC Therapeutics Quarterly report: Q2 2026 - Filings
- 7 hours ago - PTC Therapeutics reports Q2 EPS 92c, consensus 34c - TheFly
- 7 hours ago - PTC Therapeutics raises 2026 revenue view to $1.18B-$1.28B from $1.08B-$1.18B - TheFly
- 7 hours ago - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - PRNewsWire
- 7 hours ago - PTC Therapeutics Slides: Investor presentation - Filings
- 7 days ago - Hamilton Lane Board Elects Michael Schmertzler as New Independent Director - PRNewsWire